Barclays’s Odyssey Therapeutics ODTX Stock Holding History

Barclays’s Portfolio ODTX Stock Details ODTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$145K	Buy	6,523 +5,064	+347%	+$108K	﹤0.01%	4153
2026 Q2	$27.3K	Buy	+1,459	New	+$25.6K	﹤0.01%	4517

Other funds holding ODTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Lightspeed Management Company Menlo Park, California $2.03B AUM 10.68% 1-Year Est. Return

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Barclays's ODTX Position: Q3 2026 in Review

Barclays increased its Odyssey Therapeutics (ODTX) stake by 347% in Q3 2026, buying an estimated $108K and bringing the position to 6,523 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #4153.

Barclays first reported a position in ODTX in Q2 2026 and has held it in 2 quarters since. 41 funds tracked by Wall St. Rank hold ODTX as of Q3 2026.

Barclays held 6,523 shares of Odyssey Therapeutics worth $145K as of Q3 2026.
Barclays bought 5,064 Odyssey Therapeutics shares in Q3 2026, an estimated $108K.
Odyssey Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4153 holding.
Barclays first reported a position in Odyssey Therapeutics in Q2 2026 and has held it in 2 quarters since.
41 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.